We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ACTEMRA (Roche Products Pty Ltd)
Product name
ACTEMRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
tocilizumab
Registration type
EOI
Indication
Subcutaneous formulation
ACTEMRA (solution for injection) is now also indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 1 year of age and older.
ACTEMRA IV and SC can be given alone or in combination with methotrexate (MTX).